DEA pseudoephedrine proposal lacks "sufficient evidence" of OTC diversion -- NDMA.
This article was originally published in The Tan Sheet
Executive Summary
DEA PSEUDOEPHEDRINE PROPOSAL LACKS "SUFFICIENT EVIDENCE" OF OTC DIVERSION to warrant new reporting requirements, the Nonprescription Drug Manufacturers Association asserted in Jan. 2 comments to the Drug Enforcement Agency. NDMA maintained that the agency's Oct. 31 proposal, which would require retailers to report all single sales of over 24 grams pseudoephedrine base, is "legally insufficient because it does not provide sufficient evidence of OTC pseudoephedrine diversion."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning